Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 228

1.

Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis.

Sundar S, Goyal AK, Mandal AK, Makharia MK, Singh VP, Murray HW.

J Assoc Physicians India. 1999 Feb;47(2):186-8.

PMID:
10999086
2.

Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex.

Sundar S, Goyal AK, More DK, Singh MK, Murray HW.

Ann Trop Med Parasitol. 1998 Oct;92(7):755-64.

PMID:
9924533
3.

Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony.

Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW.

Ann Intern Med. 1997 Jul 15;127(2):133-7.

PMID:
9230003
4.
5.

Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis.

Sundar S, Gupta LB, Rastogi V, Agrawal G, Murray HW.

Trans R Soc Trop Med Hyg. 2000 Mar-Apr;94(2):200-4.

PMID:
10897369
6.

Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.

López-Vélez R, Videla S, Márquez M, Boix V, Jiménez-Mejías ME, Górgolas M, Arribas JR, Salas A, Laguna F, Sust M, Cañavate C, Alvar J; Spanish HIV-Leishmania Study Group.

J Antimicrob Chemother. 2004 Mar;53(3):540-3. Epub 2004 Jan 22.

PMID:
14739148
8.

Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.

Laguna F, Videla S, Jiménez-Mejías ME, Sirera G, Torre-Cisneros J, Ribera E, Prados D, Clotet B, Sust M, López-Vélez R, Alvar J; Spanish HIV-Leishmania Study Group.

J Antimicrob Chemother. 2003 Sep;52(3):464-8. Epub 2003 Jul 29.

PMID:
12888588
9.

Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.

Aguado JM, Lumbreras C, González-Vidal D; Grupo de Farmacovigilancia de Abelcet.

Clin Microbiol Infect. 2004 Sep;10(9):785-90.

10.

Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.

Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R.

Am J Trop Med Hyg. 2002 Feb;66(2):143-6.

PMID:
12135284
11.

Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions.

Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, Murray HW.

Clin Infect Dis. 2007 Sep 1;45(5):556-61. Epub 2007 Jul 23.

PMID:
17682988
12.

New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.

Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW.

Clin Infect Dis. 2008 Oct 15;47(8):1000-6. doi: 10.1086/591972.

PMID:
18781879
13.

Amphotericin B lipid complex: in visceral leishmaniasis.

Goldsmith DR, Perry CM.

Drugs. 2004;64(17):1905-11; discussion 1912-3. Review.

PMID:
15329037
14.
15.

Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.

Minodier P, Retornaz K, Horelt A, Garnier JM.

Fundam Clin Pharmacol. 2003 Apr;17(2):183-8. Review.

PMID:
12667228
16.
17.

Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies.

Mehta J, Kelsey S, Chu P, Powles R, Hazel D, Riley U, Evans C, Newland A, Treleaven J, Singhal S.

Bone Marrow Transplant. 1997 Jul;20(1):39-43.

18.

Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study.

Thakur CP, Kumar M, Pandey AK.

Am J Trop Med Hyg. 1991 Oct;45(4):435-41.

PMID:
1659239
19.

Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.

Sundar S, Mehta H, Chhabra A, Singh V, Chauhan V, Desjeux P, Rai M.

Clin Infect Dis. 2006 Mar 1;42(5):608-13. Epub 2006 Jan 20.

PMID:
16447104
20.

Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.

Jansen J, Akard LP, Wack MF, Thompson JM, Dugan MJ, Leslie JK, Mattison R.

Mycoses. 2006 Sep;49(5):397-404.

PMID:
16922792

Supplemental Content

Support Center